March 15, 2012
/PRNewswire/ -- Piedmont Pharmaceuticals, a privately held strategic pharmaceutical development, licensing, and marketing company headquartered in
, and Zhejiang Hisun Pharmaceuticals (SSE stock code 600267), a leading Chinese pharmaceutical company headquartered in
, announce the signing of a joint agreement to develop companion animal health pharmaceuticals for
and other markets worldwide.
"New products are the lifeblood of every pharmaceutical company," says
, chairman and CEO of Piedmont Pharmaceuticals. "Hisun is a globally-recognized pharmaceutical provider that demonstrates excellence in every facet of their business operations. This partnership will allow the team at
to develop and bring even more innovative animal health products to strategic business partners and pet owners worldwide."
Hua Bai, CEO and chairman of Hisun Pharmaceuticals, notes, "Hisun is very pleased to enter this partnership with Piedmont Pharmaceuticals. The
team has tremendous depth of expertise and 25 years of proven success with some of the most successful animal health products ever introduced. This product development agreement is a significant component of our strategy to become a leading global supplier of animal health pharmaceuticals. Products emerging from this collaboration will not only help Chinese consumers ensure the health of their pets, but will serve pet owners in other global markets as well."
Serving a growing market
Current estimates place
's pet population at 200 million, with that number expected to reach 500 million by 2015.[i]
is the world's second largest economy behind the U. S., and in the last 30 years, economic growth in
has averaged 8 percent gross domestic product (GDP) annually.[ii] Many analysts predict that
will become the largest economy in the world this century.
Formed by a group of industry veterans, Piedmont Pharmaceuticals develops and achieves regulatory approval for its innovative animal health and human products, then licenses them to strong commercial partners.
has licensed a number of its novel animal health products to U.S.-based Pfizer, U.K.-based Dechra Pharmaceuticals, and
-based Bayer Animal Health.
Based on sales revenues, members of
's team have been involved at some level -- including conception, development, regulatory, or marketing -- with products that represent more than 10 percent of total dollars spent in the companion animal veterinary pharmaceuticals market in the U.S. today.
Hisun supplies active pharmaceutical ingredients (APIs) to some of the world's largest pharmaceutical companies, including Pfizer, Merck, Novartis, Eli Lilly, and Alpharma.[iii] In
, Hisun entered into a joint venture framework agreement with Pfizer, the world's largest pharmaceutical company, to develop products for human health.
and Hisun will combine their strengths in research, development, regulatory, manufacturing, and distribution to improve the health and well-being of companion animals worldwide. Committed to meeting the manufacturing needs of its global expansion policy, Hisun currently has more than 200,000 square feet of new space under construction at the Fuyang site in
, including 35,000 square feet dedicated to the new animal health business.
Hisun is a leading biopharmaceutical group focused on improving patient wellbeing and quality of life. Headquartered in Taizhou (
), the company currently employs more than 3,800 people. Hisun's operations strictly follow cGMP and received ISO 14000 certification in 2001. To date, more than 40 of the company's products have passed certification by the FDA (US), EDQM (EU), TGA (
), KFDA (Korea), etc., and are sold in more than 30 countries. The company opened its U.S. headquarters in
, in 2010. For more information, visit
Piedmont Pharmaceuticals LLC is a
-based strategic pharmaceutical development and licensing company focused on human and animal health therapeutics with specific expertise in parasitology and drug delivery systems. The company discovers, develops, and achieves regulatory approval for innovative animal health and human health products, and then licenses them to strong commercial partners. Since its inception in 2001,
has licensed multiple novel patented delivery platforms to strategic partners. Through licensing agreements,
has products currently marketed in numerous countries. For more information, visit
[i] China International Business,
January 19, 2010
.[ii] Economy Watch,
January 30, 2008
, 919.293.0243, ext. 201
SOURCE Piedmont Pharmaceuticals LLC